High-fibre diet and Lactobacillus paracasei B21060 in symptomatic uncomplicated diverticular disease

World Journal of Gastroenterology

Volumn 18, Issue 41, 2012, Pages 5918-5924

  Lahner, Edith ^a   Esposito, Gianluca ^a   Zullo, Angelo ^b   Hassan, Cesare ^b   Cannaviello, Claudio ^c   Di Paolo, Maria Carla ^d   Pallotta, Lorella ^d   Garbagna, Nicoletta ^e   Grossi, Enzo ^e   Annibale, Bruno ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

^c Piazza San Bartolomeo All'Isola 21   (Italy)

^d MOLINETTE HOSPITAL   (Italy)

^e Bracco SpA   (Italy)

Author keywords

Diverticular disease; High fibre diet; Lactobacillus paracasei B21060; Probiotics; Symbiotics; Symptomatic uncomplicated diverticular disease

Indexed keywords

FLORTEC; SYNBIOTIC AGENT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOATING; CONSTIPATION; DIVERTICULOSIS; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HIGH FIBER DIET; HUMAN; INTERVIEW; LACTOBACILLUS PARACASEI; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE;

EID: 84873897299     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i41.5918     Document Type: Article

References (31)

1. Parra-Blanco A. Colonic diverticular disease: pathophysiology and clinical picture. Digestion 2006; 73 Suppl 1: 47-57
2. Stollman N, Raskin JB. Diverticular disease of the colon. Lancet 2004; 363: 631-639
3. Sheth AA, Longo W, Floch MH. Diverticular disease and diverticulitis. Am J Gastroenterol 2008; 103: 1550-1556
4. Ludeman L, Warren BF, Shepherd NA. The pathology of diverticular disease. Best Pract Res Clin Gastroenterol 2002; 16: 543-562
5. Ünlü C, Daniels L, Vrouenraets BC, Boermeester MA. A systematic review of high-fibre dietary therapy in diverticular disease. Int J Colorectal Dis 2012; 27: 419-427
6. Stollman NH, Raskin JB. Diagnosis and management of diverticular disease of the colon in adults. Ad Hoc Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999; 94: 3110-3121
7. Latella G, Pimpo MT, Sottili S, Zippi M, Viscido A, Chiaramonte M, Frieri G. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 2003; 18: 55-62
8. Colecchia A, Vestito A, Pasqui F, Mazzella G, Roda E, Pistoia F, Brandimarte G, Festi D. Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol 2007; 13: 264-269
9. Bianchi M, Festa V, Moretti A, Ciaco A, Mangone M, Tornatore V, Dezi A, Luchetti R, De Pascalis B, Papi C, Koch M. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease. Aliment Pharmacol Ther 2011; 33: 902-910
10. Humes D, Smith JK, Spiller RC. Colonic diverticular disease. Clin Evid (Online) 2011; 2011: pii0405
11. Zullo A, Hassan C, Maconi G, Manes G, Tammaro G, De Francesco V, Annibale B, Ficano L, Buri L, Gatto G, Lorenzetti R, Campo SM, Ierardi E, Pace F, Morini S. Cyclic antibiotic therapy for diverticular disease: a critical reappraisal. J Gastrointestin Liver Dis 2010; 19: 295-302
12. Maconi G, Barbara G, Bosetti C, Cuomo R, Annibale B. Treatment of diverticular disease of the colon and prevention of acute diverticulitis: a systematic review. Dis Colon Rectum 2011; 54: 1326-1338
13. Sanders ME. Probiotics: definition, sources, selection, and uses. Clin Infect Dis 2008; 46 Suppl 2: S58-61; discussion S144-151
14. Sullivan A, Nord CE. Probiotics and gastrointestinal diseases. J Intern Med 2005; 257: 78-92
15. Gill HS. Probiotics to enhance anti-infective defences in the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2003; 17: 755-773
16. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010; 59: 325-332
17. Narula N, Marshall JK. Role of probiotics in management of diverticular disease. J Gastroenterol Hepatol 2010; 25: 1827-1830
18. Andriulli A, Neri M, Loguercio C, Terreni N, Merla A, Cardarella MP, Federico A, Chilovi F, Milandri GL, De Bona M, Cavenati S, Gullini S, Abbiati R, Garbagna N, Cerutti R, Grossi E. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study. J Clin Gastroenterol 2008; 42 Suppl 3 Pt 2: S218-S223
19. Grossi E, Buresta R, Abbiati R, Cerutti R. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with acute diarrhea: a multicenter, randomized study in primary care. J Clin Gastroenterol 2010; 44 Suppl 1: S35-S41
20. Annibale B, Maconi G, Lahner E, De Giorgi F, Cuomo R. Efficacy of Lactobacillus paracasei sub. paracasei F19 on abdominal symptoms in patients with symptomatic uncomplicated diverticular disease: a pilot study. Minerva Gastroenterol Dietol 2011; 57: 13-22
21. Murphy AW, Esterman A, Pilotto LS. Cluster randomized controlled trials in primary care: an introduction. Eur J Gen Pract 2006; 12: 70-73
22. Simpson J, Neal KR, Scholefield JH, Spiller RC. Patterns of pain in diverticular disease and the influence of acute diverticulitis. Eur J Gastroenterol Hepatol 2003; 15: 1005-1010
23. Burkitt DP, Walker AR, Painter NS. Effect of dietary fibre on stools and the transit-times, and its role in the causation of disease. Lancet 1972; 2: 1408-1412
24. Humes DJ, West J. Diet and risk of diverticular disease. BMJ 2011; 343: d4115
25. Zuckerman MJ. The role of fiber in the treatment of irritable bowel syndrome: therapeutic recommendations. J Clin Gastroenterol 2006; 40: 104-108
26. Morelli L, Zonenschain D, Callegari ML, Grossi E, Maisano F, Fusillo M. Assessment of a new synbiotic preparation in healthy volunteers: survival, persistence of probiotic strains and its effect on the indigenous flora. Nutr J 2003; 2: 11
27. Morelli L, Garbagna N, Rizzello F, Zonenschain D, Grossi E. In vivo association to human colon of Lactobacillus paracasei B21060: map from biopsies. Dig Liver Dis 2006; 38: 894-898
28. Fric P, Zavoral M. The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol 2003; 15: 313-315
29. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol 2006; 40: 312-316
30. Tursi A, Brandimarte G, Giorgetti GM, Elisei W, Aiello F. Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. Int J Colorectal Dis 2007; 22: 1103-1108
31. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon. Hepatogastroenterology 2008; 55: 916-920